Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised t
GSK plc. (GSK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
05:00pm, Wednesday, 05'th Feb 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company's possible
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights
04:17pm, Wednesday, 05'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R.
03:16pm, Wednesday, 05'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) on behalf of investors concerning the Company's possi
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
12:26pm, Wednesday, 05'th Feb 2025
GSK Plc's (GSK) U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a stock buyback on the back of optimism about sales of its new drugs.
GSK plc (GSK) Q4 2024 Earnings Call Transcript
11:52am, Wednesday, 05'th Feb 2025
GSK plc (NYSE:GSK ) Q4 2024 Earnings Conference Call February 5, 2025 5:45 AM ET Company Participants Dame Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Julie Brown - C
NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
10:06am, Wednesday, 05'th Feb 2025
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
09:04am, Wednesday, 05'th Feb 2025
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales. The post GSK Surges 7% After Bumping Its 2031 Outlook To North
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
08:06am, Wednesday, 05'th Feb 2025
GSK (GSK) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.72 per share a year ago.
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
08:05am, Wednesday, 05'th Feb 2025
Wednesday, GSK Plc GSK reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 bil
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
04:38am, Wednesday, 05'th Feb 2025
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early tra
GSK shares rise 5% as it navigates vaccines woes to upgrade sales target
04:28am, Wednesday, 05'th Feb 2025
GSK PLC (LSE:GSK, NYSE:GSK) shares climbed 5% in early trading on Wednesday after the drugs giant appeared to shrug off vaccine-related woes and mollified the City by raising its long-term sales targ
GSK upgrades long-term sales target; but Arexvy's struggles are confirmed
02:44am, Wednesday, 05'th Feb 2025
GSK PLC (LSE:GSK, NYSE:GSK) has raised its long-term revenue forecast, now expecting sales to exceed £40 billion by 2031, up from its previous £38 billion target. The upgrade comes after what the c
